Literature DB >> 27838783

The FGF23 and Klotho system beyond mineral metabolism.

Makoto Kuro-O1.   

Abstract

FGF23 is a bone-derived hormone that acts primarily on the kidney to induce phosphaturia and suppress synthesis of 1,25-dihydroxyvitamin D3. The unique feature of FGF23 is that it requires Klotho as an obligate co-receptor. The FGF23-Klotho system has emerged as an endocrine axis indispensable for maintaining phosphate homeostasis. Mineral and bone disorders associated with chronic kidney disease (CKD-MBD) can be viewed as a series of events triggered by a compensatory response of the FGF23-Klotho system to excess phosphate intake relative to the residual nephron number. Furthermore, the fact that disruption of the FGF23-Klotho system causes phosphate retention and a syndrome resembling aging in mammals has led to the notion that phosphate accelerates aging. The aging-like pathology caused by phosphate, or phosphatopathy, may be unique to the higher organisms having the Klotho gene and provides new insights into the molecular mechanism of aging in humans.

Entities:  

Keywords:  FGF23; Phosphatopathy; αKlotho

Mesh:

Substances:

Year:  2016        PMID: 27838783     DOI: 10.1007/s10157-016-1357-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  44 in total

1.  Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system.

Authors:  Hiroshi Tsujikawa; Yoko Kurotaki; Toshihiko Fujimori; Kazuhiko Fukuda; Yo-Ichi Nabeshima
Journal:  Mol Endocrinol       Date:  2003-10-03

2.  Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule.

Authors:  Ming Chang Hu; Mingjun Shi; Jianning Zhang; Johanne Pastor; Teruyo Nakatani; Beate Lanske; M Shawkat Razzaque; Kevin P Rosenblatt; Michel G Baum; Makoto Kuro-o; Orson W Moe
Journal:  FASEB J       Date:  2010-05-13       Impact factor: 5.191

Review 3.  Chronic kidney disease: a clinical model of premature aging.

Authors:  Peter Stenvinkel; Tobias E Larsson
Journal:  Am J Kidney Dis       Date:  2013-01-26       Impact factor: 8.860

Review 4.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.

Authors:  Ming Chang Hu; Kazuhiro Shiizaki; Makoto Kuro-o; Orson W Moe
Journal:  Annu Rev Physiol       Date:  2013       Impact factor: 19.318

5.  Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.

Authors:  Yoshiko Shimamura; Kazu Hamada; Kosuke Inoue; Koji Ogata; Masayuki Ishihara; Toru Kagawa; Mari Inoue; Shimpei Fujimoto; Mika Ikebe; Kenji Yuasa; Shigeo Yamanaka; Teturo Sugiura; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2012-03-29       Impact factor: 2.801

6.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

7.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

8.  Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition.

Authors:  Ricardo Villa-Bellosta; Víctor Sorribas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-02-12       Impact factor: 8.311

9.  Salt-sensitive hypertension in transgenic mice overexpressing Na(+)-proton exchanger.

Authors:  M Kuro-o; K Hanaoka; Y Hiroi; T Noguchi; Y Fujimori; S Takewaki; M Hayasaka; H Katoh; A Miyagishi; R Nagai
Journal:  Circ Res       Date:  1995-01       Impact factor: 17.367

10.  In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels.

Authors:  Mutsuko Ohnishi; Teruyo Nakatani; Beate Lanske; M Shawkat Razzaque
Journal:  Circ Cardiovasc Genet       Date:  2009-09-21
View more
  33 in total

1.  An introduction to CKD-MBD research: restart for the future.

Authors:  Masafumi Fukagawa; Masaaki Inaba; Keitaro Yokoyama; Takashi Shigematsu; Ryoichi Ando; Ken-Ichi Miyamoto
Journal:  Clin Exp Nephrol       Date:  2017-03       Impact factor: 2.801

2.  Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease.

Authors:  Xiaotian Zhong; Srinath Jagarlapudi; Yan Weng; Mellisa Ly; Jason C Rouse; Kim McClure; Tetsuya Ishino; Yan Zhang; Eric Sousa; Justin Cohen; Boriana Tzvetkova; Kaffa Cote; John J Scarcelli; Keith Johnson; Joe Palandra; James R Apgar; Suma Yaddanapudi; Romer A Gonzalez-Villalobos; Alan C Opsahl; Khetemenee Lam; Qing Yao; Weili Duan; Annette Sievers; Jing Zhou; Darren Ferguson; Aaron D'Antona; Richard Zollner; Hongli L Zhu; Ron Kriz; Laura Lin; Valerie Clerin
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

3.  The predictive value of Klotho polymorphism, in addition to classical markers of CKD-MBD, for left ventricular hypertrophy in haemodialysis patients.

Authors:  Branislav Apostolović; Tatjana Cvetković; Nikola Stefanović; Svetlana Apostolović; Marija Anđelković Apostolović; Branka Mitić; Radmila Veličković Radovanović; Karolina Paunović; Aleksandra Ignjatović; Mina Cvetković; Nataša Stević; Dusica Pavlović
Journal:  Int Urol Nephrol       Date:  2019-06-11       Impact factor: 2.370

4.  Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

Authors:  Brian A Bergmark; Jacob A Udell; David A Morrow; Petr Jarolim; Julia F Kuder; Scott D Solomon; Marc A Pfeffer; Eugene Braunwald; Marc S Sabatine
Journal:  Eur J Heart Fail       Date:  2019-02-18       Impact factor: 15.534

Review 5.  Potential application of klotho in human chronic kidney disease.

Authors:  Javier A Neyra; Ming Chang Hu
Journal:  Bone       Date:  2017-01-20       Impact factor: 4.398

6.  Fibroblast Growth Factor 23 and Klotho Are Associated With Trabecular Bone Score but Not Bone Mineral Density in the Early Stages of Chronic Kidney Disease: Results of the Cross-Sectional Study.

Authors:  Z Kužmová; M Kužma; A Gažová; M Kovářová; P Jackuliak; Z Killinger; J Kyselovič; J Payer
Journal:  Physiol Res       Date:  2021-11-30       Impact factor: 1.881

7.  Associations of serum soluble klotho and fibroblast growth factor 23 with carotid artery calcification in patients undergoing continuous ambulatory peritoneal dialysis: A retrospective study.

Authors:  Naifeng Guo; Xu Chen; Yingjie Cao; Guoyuan Lu
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

8.  A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts.

Authors:  Takahiro Kanai; Kazuhiro Shiizaki; Hiroyuki Betsui; Jun Aoyagi; Takanori Yamagata
Journal:  CEN Case Rep       Date:  2018-05-16

Review 9.  Novel treatment strategies for chronic kidney disease: insights from the animal kingdom.

Authors:  Peter Stenvinkel; Johanna Painer; Makoto Kuro-O; Miguel Lanaspa; Walter Arnold; Thomas Ruf; Paul G Shiels; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2018-01-15       Impact factor: 28.314

Review 10.  Chronic Kidney Disease-Mineral and Bone Disorder in Asia.

Authors:  Masafumi Fukagawa; Hirotaka Komaba
Journal:  Kidney Dis (Basel)       Date:  2017-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.